Tag: CYTR

KNDI, PPHM & Extended Watchlist

Kandi Technologies Group, Inc. KNDI

This morning, we are revisiting a play that has been periodically appearing on our Extended Watchlists since this summer. Following a July 15th alert, we would see KNDI dip as low as 4.41 (07/23). We continued to monitor the stock through to September, as it went on to hit a high of 9.20 (10/26), marking an increase of 109% in roughly three month’s time. However, our adventures with KNDI had only just begun.

By early November, it had settled back to a low of 6.15, and it hasn’t looked back since. Moderate gains gave way to full-on breakout mode on Friday as the stock rocketed to a high of 10.4784, marking a gain of 70% off of its most recent low, and a 138% rise from our original alert low of 4.41. This huge move came just a few days after the following announcement:

This is definitely a story that we will continue to follow in the New Year, as the company expects to increase its delivery of electric vehicles. CEO Hu Xiaoming recently stated: “In 2014, we expect our EV business may surpass our legacy go-cart business and become a major revenue generator for the company,”

More information : http://www.kandivehicle.com

Peregrine Pharmaceuticals, Inc. PPHM

PPHM is an old-time favorite of ours that we wanted to call attention to this morning, as the stock is undergoing some notable pre-market trading action. From lows (1.25) following our most recent alert on PPHM is gapping up significantly, currently trading in the high 1.40’s on a PR fresh out this morning. We’re very interested to see how far the current trend will carry, so keep an eye peeled on PPHM.


Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer

Company Launches www.SunriseTrial.com to Assist Patients and Physicians

TUSTIN, CA, Dec 30, 2013 (Marketwired via COMTEX) — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced the opening to enrollment of its SUNRISE trial at leading oncology centers in the United States. SUNRISE is a pivotal Phase III clinical trial comparing the company’s investigational immunotherapy bavituximab plus the chemotherapy docetaxel against placebo plus the chemotherapy docetaxel in patients with second-line non-small cell lung cancer (NSCLC). This trial will enroll approximately 600patients from more than 100 medical centers worldwide. >> FULL PR

Extended Watchlist:
AMMX, PROW, BIOL, CYTR, AVL(Coming off double-bottom)

TGRO, OLIE, PROW, ARIA & Extended Watchlist

Tiger Oil & Energy, Inc.  TGRO

We’ve been following TGRO since Monday of last week, at which time the stock was trading as low .36. After running up to the low .60’s, we observed the stock pull back to .38. We were encouraged to find that it held support above our initial alert low, as higher lows following a pullback are often a good sign.

Sure enough, since then, the stock has been stair-stepping its way up to hit yesterday’s high of .75. That marks a 108% overall move from our initial alert price, and up to 97% from TGRO’s most recent low of .38.

Olie, Inc. OLIE

On Wednesday, OLIE was an excellently timed call for us. We had the opportunity to make up to 147% profit as the stock ran from .0082-.02 before pulling back significantly to close at .0097.

Following up in yesterday’s report, we stated: “…with the kind of volatility we’re seeing out of OLIE, we definitely want to pay attention heading into week’s end. Further opportunities could certainly present themselves.” Our call turned out to be spot-on once again.

The stock shot right out of the gate to make a rapid 55% move from .0097 to .015. Then, following a pullback to .0108, it ran again, this time to .016, a 48% spike.

That brought our two-day total cumulative gains on OLIE to an impressive 250%

Progress Watch Corp. PROW

PROW popped up on our abnormal activity scanner yesterday, and we had to make certain to pass it along today.

Chart conditions appear to be favorable: The RSI is ready to breach into the power zone, and the MACD recently experienced a bullish cross. The 50DMA is rising sharply toward the 200DMA that should lead to a golden cross in the week and months ahead. Presently, we’re looking to see PROW push through and hold support above its 200DMA at  .0072.

We also want to point out that PROW boasts an extremely tight share structure, with only 25.1 million in the float as of March of this year. A stock trading at this increment with such a low float needs only a relatively small amount of buying pressure to produce significant gains.

ARIAD Pharmaceuticals, Inc. ARIA

We’ve been tracking ARIA ever since November 26th. Since that time, we’ve observed the stock trading as low as 3.80. ARIA has been picking up steam over the past few sessions, posting higher highs and higher lows for three consecutive days.

Yesterday it hit a high of 5.58, marking an increase of 47% over recent lows.

Extended Watchlist:
PLPE (Gapping Down on Large Premarket Volume), AMRN, ORMP, TSEM, CLWT, CYTR, BCRX,

Blue Horseshoe: The Week in Review

For as long as we can remember following the Penny Stock Rumble, we can’t recall a time when a newsletter took the top spot on 3 out of 4 days, but with yesterday’s session, we did in fact reach that difficult achievement! We were anticipating our first ever hat-trick, and we were not disappointed. The following video outlines some of this week’s biggest successes:

Tiger Oil & Energy, Inc. TGRO

We started off Monday with TGRO, which traded as low as .36, and hit .635 on Tuesday for a 76% gain. It would then dip back to .38 before reversing again and surging as high as .62 yesterday for up to 63% on the rebound.

That brought this week’s cumulative gains from TGRO to a total of 139%.

BG Medicine, Inc. BGMD

Next came BGMD, which we spotted on Tuesday trading as low as .6115. We would witness this play running to a high of 1.70 by Wednesday, giving us the opportunity at 178% in possible gains.

CytRx Corp. CYTR

Last but not least, was Wednesday’s alert of CYTR, which looks like it could sprout legs again today. CYTR was as low as 3.45 at the time of our initial alert, and hit a high of 6.36 yesterday, racking in 84% in gains!

This morning, CYTR is gapping up once again, trading in the 6.55 range; if the breakout continues, consider it another triple-digit winner for us.

This was the play that gave us our third winning appearance on the Rumble:

Coronado BioSciences, Inc. CNDO

CNDO jumped out at us as a stock with a serious gap to fill on the chart. As you can see below, back in October the stock fell off a cliff from the $6-8 range all the way down to present levels.

This is a potential play that we’ll want to monitor closely moving forward, because a break of the 50DMA could very well lead to the filling of at least a portion of that gap, a move which would carry with it some significant gains.

With calls like these this week, we’ve made other newsletters obsolete! Nowhere else can you find both diversification into many areas of finance(from microcaps, to big-boards, to options-trading & more), and winning picks on such a consistent basis. Why would you go anywhere else? The word ‘quit’ is not in our vocabulary, which is why we’ll come back time and time again, providing our readers with the highest-quality picks available! We’re wrapping up another hugely successful week, so be sure to get back with us on Monday when we’ll do it all over again!

Extended Watchlist:
SFBR, PLUG, MACK, CLSN, ICLD, PVG, PTIX, ETAK